Cyclarity Therapeutics
Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases.
Cyclarity develops easy-to-use drugs that prevent common age-related conditions such as atherosclerosis, heart-attack and stroke by addressing the root cause - a build-up of arterial plaque.
The company's technology removes arterial plaque by clearing the non-degradable cholesterol that accumulates within cells in the arterial walls.
Previously called Underdog Pharmaceuticals, the company changed its name in 2022.
Underdog was built from an SRF flagship program that has driven two years of applied development designed to explore and repair the underlying causes of cardiovascular disease. Its co-founders are Matthew O’Connor, Ph.D., and Michael Kope, formerly the Vice President of Research and the founding Chief Executive Officer, respectively, of SRF.
Hoping to start clinical trials in the UK in 2023.
Visit website: https://underdogpharma.com/
See also: 
SENS Research Foundation
- Non-profit organization focused on transforming the way the world researches and treats age-related diseases
Details last updated 03-Feb-2020
People at Cyclarity Therapeutics
Matthew O’Connor
Co-Chief Executive Officer and Co-founder of Cyclarity Therapeutics (former Underdog Pharmaceuticals)
Cyclarity Therapeutics News
Lifespan.io speaks to Cyclarity’s CEO for an update on its novel atherosclerosis treatment
Lifespan.io (LEAF) - 19-Feb-2024
The company is developing a drug called UDP-003 to treat the disease
Read more...Reason reports back from October's Rejuvenation Startup Summit
Fight Aging! - 19-Oct-2022
Some really exciting developments with quite a few in clinical trials
Read more...Racing for the lead... Underdog becomes Cyclarity Therapeutics
Longevity Technology - 20-Jun-2022
Also announces move to Buck Institute for Research on Aging
Read more...Underdog pharmaceuticals secures $10m funding from Kizoo ventures
Longevity Technology - 23-Sep-2021
Funds to bring affordable and effective age-related therapies to the public
Read more...'Innovation Passport' awarded for Underdog's novel compound intended for treating heart diseases
Longevity Technology - 09-Sep-2021
Safe and potential compound shows disease-modifying effect by removing toxic cholesterol from blood
Read more...Two drug molecules delivered via nanoparticles to combat atherosclerosis
Lifespan.io (LEAF) - 26-Jun-2020
Success in mice model gives hope for fighting cholesterol-associated inflammatory diseases
Read more...Fight Aging! reports back from SENS Research Foundation Pitch Day
Fight Aging! - 20-Jan-2020
When some of these succeed in human trials even more money will pile in to fund further advances
Read more...
